LASMED LTD LIABILITY CORP — Department of Health and Human Services SBIR Phase I: 200
LASMED LTD LIABILITY CORP — SBIR Phase I award from Department of Health and Human Services.
- Amount
- $225,000
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase I
- Topic
- 200
- Solicitation
- PA14-058
- NAICS
- —
- Place of performance
- CA
- Period
- 2015-09-21 → 2017-02-28
Description
DESCRIPTION provided by applicant Peripheral neuropathic pain NP is a significant public health problem debilitating both patients and their families and has a substantial impact on the health care system Over million people suffer worldwide from diabetes related neuropathic pain DPN The pain associated with diabetic nerve damage has been shown to involve the activity in heat sensitive trpv nociceptors in the skin For this reason a strategy wa developed to deplete these neurons by using the trpv agonist capsaicin However capsaicin as a chemical agonist at trpv has non specific toxic effects leading to painful inflammation and depletion of non nociceptive neurons in the skin such as those that transduce touch Despite the fact that high concentration capsaicin patches generally do help with DPN they have not achieved widespread use in large part because of these non specific toxicity issues Thus there is an unmet need for a specific trpv agonist that could be used to deplete nociceptor terminals in the skin without the adverse effects of capsaicin The goal of the experiments proposed here is to determine whether diode laser DL pulses which produce heat deep within the skin will be able to not only activate these nociceptors but also deplete them and so produce analgesia As heat is a non chemical and highly specific physical agonist for trpv this depletion should not require the off target toxic effects that are observed with capsaicin treatments Experiments described here use pigs which have skin most similar to humans as an experimental model to determine whether and to what extent different doses of DL pulses can selectively and dose dependently deplete cutaneous nerve fiber endings as indicated by decreased labeling with the neuronal markers PGP TRV These experiments will furthermore determine whether this depletion can be achieved without reaching surface temperatures which cause substantive skin damage as assessed by standard hematoxylin and eosin histological techniques Surface temperatures will be monitored using a high speed thermal camera to aid in this goal as well as to provide a basis for the late development of a next generation scanning DL device which will incorporate temperature feedback Thus these experiments are intended to allow optimization of doses of DL irradiation that can be rapidly translated to human clinical testing and eventually to an important new tool for the treatment of patients with painful peripheral neuropathy PUBLIC HEALTH RELEVANCE The long term goal of this project is to develop a novel non pharmacologic approach to the treatment of peripheral neuropathic pain using a diode laser radiation The experiments proposed here build on our expertise to enable rapid translation of this technology to patients